Mylavarapu Sanghamitra, Kumar Harsh, Kumari Smita, Sravanthi L S, Jain Misti, Basu Aninda, Biswas Manjusha, Mylavarapu Sivaram V S, Das Asmita, Roy Monideepa
Invictus Oncology Pvt. Ltd., New Delhi, India.
Department of Biotechnology, Delhi Technological University, New Delhi, India.
Front Oncol. 2019 Feb 15;9:54. doi: 10.3389/fonc.2019.00054. eCollection 2019.
Colorectal cancer is the third major cause of cancer-related mortality worldwide. The upward trend in incidence and mortality rates, poor sensitivity to conventional therapies and a dearth of early diagnostic parameters pose a huge challenge in the management of colorectal cancer in India. Due to the high level of genetic diversity present in the Indian population, unraveling the genetic contributions toward pathogenesis is key for understanding the etiology of colorectal cancer and in reversing this trend. We have established a novel cell line, MBC02, from an Indian colorectal cancer patient and have carried out extensive molecular characterization to unravel the pathological alterations in this cell line. In-depth molecular analysis of MBC02 revealed suppression of E-cadherin expression, concomitant with overexpression of EMT related molecules, which manifested in the form of highly migratory and invasive cells. Loss of membrane-tethered E-cadherin released β-catenin from the adherens junction resulting in its cytoplasmic and nuclear accumulation and consequently, upregulation of . MBC02 also showed dramatic transcriptional upregulation of β-catenin. Remarkably, we observed significantly elevated proteasome activity that perhaps co-evolved to compensate for the unnaturally high mRNA level of β-catenin to regulate the increased protein load. In addition, there was substantial misregulation of other clinically relevant signaling pathways that have clinical relevance in the pathogenesis of colorectal cancer. Our findings pave the way toward understanding the molecular differences that could define pathogenesis in cancers originating in the Indian population.
结直肠癌是全球癌症相关死亡的第三大主要原因。发病率和死亡率呈上升趋势,对传统疗法敏感性差以及早期诊断参数匮乏,给印度的结直肠癌治疗带来了巨大挑战。由于印度人群存在高度的遗传多样性,阐明遗传因素对发病机制的贡献是理解结直肠癌病因及扭转这一趋势的关键。我们从一名印度结直肠癌患者身上建立了一种新的细胞系MBC02,并进行了广泛的分子特征分析,以揭示该细胞系中的病理改变。对MBC02的深入分子分析显示E-钙黏蛋白表达受到抑制,同时上皮-间质转化相关分子过表达,表现为细胞具有高度迁移性和侵袭性。膜结合型E-钙黏蛋白的缺失使β-连环蛋白从黏附连接处释放出来,导致其在细胞质和细胞核中积累,从而上调了……MBC02还显示出β-连环蛋白的转录显著上调。值得注意的是,我们观察到蛋白酶体活性显著升高,这可能是共同进化以补偿β-连环蛋白异常高的mRNA水平,从而调节增加的蛋白质负荷。此外,其他在结直肠癌发病机制中具有临床相关性的信号通路也存在大量失调。我们的研究结果为理解可能定义印度人群起源癌症发病机制的分子差异铺平了道路。